Transcriptomics

Dataset Information

0

CHRM3 is a novel prognostic factor of poor prognosis and promotes GBM progression via activation of oncogenic invasive growth factors


ABSTRACT: Glioblastoma (GBM) is the most aggressive cancer in brain and contains a high mortality ratedue to lack of effective treatment strategy. Molecular mechanisms of GBM characteristic invasive growth are urgently need to improve the poor prognosis. Via single nuclear-sequences of primary and recurrent GBM samples, level of the M3 muscarinic acetylcholine receptor (CHRM3) was significantly higher in recurrent samples. Moreover, immunohistochemical staining of an array of glioma samples showed that high levels of CHRM3 is correlated to poor prognosis of glioma, consistent with The Cancer Genome Atlas (TCGA) database. Knockdown of CHRM3 retarded glioma cell growth and invasion. In vivo assay of orthotopic glioma animal model indicated that inhibition of CHRM3 significantly suppressed glioma progression with prolonged survival time. Transcriptome analysis revealed that CHRM3 knockdown significantly reduced array of classic factors involved in cancer invasive growth including MMP1/MMP3/MMP10/MMP12 and CXCL1/CXCL5/CXCL8. Taken together, our study identified that CHRM3 is a new and important factor of GBM progression via regulation of multiple oncogenic genes and these results provide a new biomarker for prognosis and therapy of GBM patients.

ORGANISM(S): Homo sapiens

PROVIDER: GSE220083 | GEO | 2022/12/10

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2010-05-27 | E-GEOD-21570 | biostudies-arrayexpress
2024-07-23 | MODEL2407230001 | BioModels
| PRJNA908781 | ENA
2023-05-01 | GSE205513 | GEO
2023-05-01 | GSE205512 | GEO
2023-06-01 | GSE206917 | GEO
2018-02-27 | E-MTAB-6371 | biostudies-arrayexpress
2010-04-29 | GSE21570 | GEO
2020-10-08 | GSE142827 | GEO
2020-10-08 | GSE142825 | GEO